0
0
Read Time:4 Minute, 52 Second
NEW DELHI — In a comprehensive update delivered to the Lok Sabha on Thursday, August 6, 2026, the Union Ministry of Chemicals and Fertilizers reaffirmed the government’s commitment to curbing escalating healthcare expenses through stringent price controls and stricter ethical standards for pharmaceutical marketing.
Minister of State Smt. Anupriya Patel outlined the dual framework currently safeguarding consumers: strict maximum retail price ceilings enforced by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs (Prices Control) Order, 2013 (DPCO, 2013), and the newly implemented Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024. Together, these measures aim to lower out-of-pocket medical costs for millions of households while curtailing unethical promotional tactics between pharmaceutical representatives and medical professionals.
Defining the Guardrails: How Drug Price Regulation Works
At the heart of India’s drug affordability strategy lies the DPCO, 2013, framed on the principles of the National Pharmaceutical Pricing Policy, 2012. Under this decree, the NPPA sets fixed “ceiling prices” for essential formulations categorized under Schedule-I of the order. These ceiling prices are calculated using market-based data and apply uniformly across the country.
For medications classified as “non-scheduled formulations”—drugs not listed under Schedule-I—the regulation imposes a mandatory annual cap: manufacturers are strictly prohibited from increasing the Maximum Retail Price (MRP) by more than 10% within any preceding 12-month period.
+-------------------------------------------------------------+
| PHARMACEUTICAL PRICE REGULATION |
+-------------------------------+-----------------------------+
|
+-------------------+-------------------+
| |
v v
+-------------------------+ +--------------------------+
| SCHEDULE-I FORMULATIONS| | NON-SCHEDULED FORMULAS |
+-------------------------+ +--------------------------+
| Capped by NPPA ceiling | | Annual MRP increases |
| prices based on market | | strictly capped at a |
| data and evaluations. | | maximum of 10%. |
+-------------------------+ +--------------------------+
To maintain regulatory fairness, the NPPA operates through a public review process. Draft price calculation sheets are published on the official NPPA portal for 10 working days, inviting feedback, objections, and additional data from manufacturers, healthcare providers, and consumer advocacy groups before final price notifications are legally issued.
“Transparency in price fixation is critical for maintaining market trust,” noted Dr. Rajesh Kumar, a public health specialist and health economics expert not affiliated with the ministry. “By placing calculation methodologies in the public domain prior to finalization, regulators strike a balance between consumer affordability and the operational viability of pharmaceutical producers.”
To enforce compliance, state-level Price Monitoring and Resource Units (PMRUs) and State Drugs Controllers perform routine market spot-checks and review database reports. By law, manufacturers must clearly print the MRP on all retail packaging, and sellers are prohibited from charging above the printed label or the official price list.
Cracking Down on Unethical Marketing Practices
Beyond direct price caps, the Department of Pharmaceuticals (DoP) introduced the updated Uniform Code for Pharmaceutical Marketing Practices (UCPMP) in March 2024 to target indirect drivers of drug costs—namely, aggressive marketing practices targeting healthcare providers.
The UCPMP establishes clear boundaries for interactions between medical representatives and Registered Medical Practitioners (RMPs):
-
Strict Ban on Gifts and Perks: Expressly prohibits offering gifts, monetary incentives, free travel, or personal hospitality to doctors and their immediate family members.
-
Mandatory Disclosures: Requires pharmaceutical firms to submit self-declarations of compliance and publicly disclose expenses related to continuing medical education (CME) events, seminars, and workshops.
-
Tax Disallowances: Clarifies that promotional expenses failing to conform with the UCPMP and the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, will not qualify for tax deductions under the Income-tax Act, 1961.
Violation of the code triggers a two-tier adjudication framework overseen by the Department of Pharmaceuticals. Penalties range from formal public reprimands and forced corrective media statements to the mandatory recovery of illegal gifts or monetary benefits from recipients.
“Addressing unethical marketing is as essential to patient welfare as price ceilings,” explained Dr. Sunita Rao, a bioethics researcher. “When prescribing decisions are influenced by promotional incentives rather than clinical necessity, patients bear both financial and health burdens. Tax-disallowing non-compliant marketing expenditures adds a real financial penalty for non-compliance.”
Expanding Access: Government Affordability Initiatives
Price controls work alongside several public health safety-net initiatives designed to extend affordable care to lower-income populations:
| Program / Scheme | Target Benefit & Coverage Mechanism |
| Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) | Operates over 20,000 Janaushadhi Kendras, offering high-quality generic medicines at 50% to 80% lower costs than branded equivalents. |
| Ayushman Bharat (AB-PMJAY) | Grants health coverage of up to ₹5 lakh per family per year for secondary and tertiary hospitalization, covering inpatient drug costs. |
| Free Drugs Service Initiative (NHM) | Supplies essential medicines free of charge across public healthcare facilities, from Primary Health Centres (PHCs) to district hospitals. |
| AMRIT Pharmacy Outlets | Provides specialized treatments for cancer, cardiovascular conditions, and surgical implants at discounts averaging up to 50%. |
| Rashtriya Arogya Nidhi (RAN) | Delivers direct financial assistance to patients living below the poverty line who require treatment for life-threatening illnesses. |
Market Impacts and Ongoing Challenges
While price caps and ethical codes protect healthcare consumers, industry analysts point to potential trade-offs. Setting ceiling prices too close to baseline production costs can lead to supply disruptions if manufacturers alter product lines away from regulated formulations.
Furthermore, consumer rights organizations note that monitoring compliance across millions of retail pharmacies nationwide remains a significant operational challenge. Expanding the capacity of state-level Price Monitoring and Resource Units (PMRUs) will be vital to catching price violations early and ensuring that public price lists translate directly into lower receipts at the pharmacy counter.
References
-
Government Announcement: Ministry of Chemicals & Fertilizers, Press Information Bureau (PIB) Delhi, Release ID: Statement on “Fixation and Regulation of Prices of Drugs,” presented in Lok Sabha by MoS Smt. Anupriya Patel (August 7, 2026).
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
